DAIICHI SANKYO, INC.

The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.

DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.

Hiroyuki Okuzawa assumed leadership of Daiichi Sankyo two months ago, inheriting a company strengthened by three major pharmaceutical licensing deals worth up to $27 billion based on ADC technology.

AbbVie's antibody drug conjugate Temab-A achieved a 63% overall response rate in patients with advanced EGFR-mutated non-small cell lung cancer in Phase I trial results presented at ASCO 2025.

The phase II TUXEDO-3 trial showed patritumab deruxtecan (HER3-DXd) achieved intracranial response rates of 23.8% in metastatic breast cancer and 30% in advanced non-small cell lung cancer patients with active brain metastases.

A multi-institutional study of 1,476 patients found that 75% of those with grade 1 interstitial lung disease (ILD) were successfully rechallenged with trastuzumab deruxtecan, remaining on therapy for a median of 215 days.

Merck KGaA's antibody-drug conjugate precemtabart tocentecan demonstrated safety and tolerability in a Phase Ib trial for metastatic colorectal cancer patients.

Merck and Daiichi Sankyo withdrew their FDA application for patritumab deruxtecan, an antibody-drug conjugate targeting EGFR-mutated non-small cell lung cancer, after the drug failed to demonstrate overall survival benefit.

Daiichi Sankyo and Merck voluntarily withdrew their Biologics License Application for patritumab deruxtecan in EGFR-mutated NSCLC after the confirmatory HERTHENA-Lung02 Phase 3 trial failed to demonstrate statistically significant overall survival benefit.

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.